AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 101 min read$UTHR

ROTHBLATT MARTINE A sold $4.8M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $501.84 ($493.81–$509.00, $4.77M total) across 14 trades on 2026-09-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Sep 10, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 8:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Neutral
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRNeutralLow
01

Why it matters

The disclosed sale provides fresh data on insider activity but offers limited actionable insight due to its pre‑arranged nature.

02

Market read

Primary disclosure of an insider sale; modest relevance for short‑term traders monitoring UTHR.

03

What to watch

The 10b5‑1 plan means the sale may not reflect current sentiment; market may already price it in.

Relevance 5/10Novelty 6/10Timing: post‑market 2026‑09‑09

Background

SEC Form 4 filing reports insider transactions for public companies.

Company-level read

Ticker impact

$UTHRNeutralMedium confidence
Context

Chairperson & CEO sold 9,500 shares for $4.8M via a pre‑arranged 10b5‑1 plan on 2026‑09‑09.

Expected impact

Potential modest dip in UTHR price over the next few days.

Evidence & confidence

The sale size is moderate relative to total holdings and executed under a 10b5‑1 plan, limiting informational value.

Market effects

Sector

Minimal impact on the biotech/pharma sector; insider sales are routine.

Regional

No significant regional effect; UTHR trades primarily on US exchanges.

Global

Limited global relevance; the filing is a standard SEC disclosure.

Counterpoint

What could challenge this read

The sale could be a red flag if the CEO is reducing exposure ahead of undisclosed issues.

Key entities

  • Company
    United Therapeutics Corp

    Biopharmaceutical company listed on NASDAQ under ticker UTHR.

  • Executive
    Martine A. Rothblatt

    Chairperson & CEO of United Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 28
$UTHRMed

United Therapeutics Receives FDA Clearance to Begin Clinical Trial of Inhaled PAH Treatment

United Therapeutics (UTHR) received FDA clearance to start clinical trials for Treprostinil-Iloprost SMI, an inhaled treatment for pulmonary arterial hypertension (PAH). The phase 1 trial will assess safety and tolerability. The therapy aims to address symptom flare-ups between maintenance doses. UTHR plans a phase 2 trial in 2027 if initial results are positive. PAH affects around 500,000 people globally.

finance.yahoo.com2 min
OCT 28
$UTHRMed

FDA clears a trial of a two-drug inhaler that could be the first as-needed therapy for lung artery disease.

The FDA approved a trial for Treprostinil-Iloprost SMI, a potential first as-needed inhaler therapy for pulmonary arterial hypertension (PAH). United Therapeutics plans a phase 1 study in 2026, with a phase 2 study in PAH patients anticipated in 2027. The therapy combines treprostinil and iloprost, aiming to provide episodic symptom relief. United Therapeutics aims to expand its PAH treatment portfolio.

stocktitan.net2 min